= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Lageveen-Kammeijer

MSACL 2018 EU Abstract

Topic: Glycomics

Podium Presentation in the Ether on Wednesday at 14:50 (Chair: TBA)

Development of MS-based Prostate-Specific Antigen Test with In-Depth Glycosylation Analysis

Guinevere S.M. Lageveen-Kammeijer (Presenter)
Center for Proteomics and Metabolomics, LUMC

Presenter Bio(s): Guinevere S. M. Lageveen-Kammeijer received a BSc degree in Biotechnology - Forensic Sciences from University of Applied Science van Hall Larenstein, Leeuwarden, NL followed by a MSc in Analytical Chemistry at the VU University, Amsterdam, NL.

Since June 2013, she is a PhD candidate at the Center for Proteomics and Metabolomics at Leiden University Medical Center, NL under the supervision of Prof. Dr. Manfred Wuhrer. Her main research project involves exploring the glycosylation of prostate-specific antigen for a better defined biomarker for prostate cancer. In addition, she studies the possibilities for in-depth analysis of glycans and intact glycoproteins with CE-ESI-MS for biomarker discovery and the characterization of biopharmaceuticals.

Furthermore, she is a member of the organization committee of the Netherlands Area Biotech (NLab) Discussion group supported by the CASSS.

Authors: Guinevere S.M. Kammeijer(1), Jan Nouta(1), Anna Kałuża(1,2), Wei Wang(1), Noortje de Haan(1); L. Renee Ruhaak(3), Kasper M. Siliakus(3); Mervin M. Pieterse(3), Theo M. de Reijke(4), Yuri E.M. van der Burgt(1,3), Christa M. Cobbaert(3); Manfred Wuhrer (1)
(1) Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands, (2) Department of Chemistry and Immunochemistry, Wrocław Medical University, Wrocław, Poland, (3) Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, The Netherlands, (4) Urology Department, Academic Medical Center, Amsterdam, The Netherlands


The diagnostic test for prostate cancer (PCa) based on glycoprotein prostate-specific antigen (PSA) is widely known for its lack in specificity. Recently, we established a PSA glycomics assay that allows identifying and relatively quantifying the glycosylation profile of PSA in a non-invasive manner after affinity capturing from patients’ urine. The applicability of this assay is further explored for other biofluids such as seminal plasma and serum. Potentially, alterations in the glycosylation pattern will provide better diagnostic and prognostic tools for fertility conditions (seminal plasma) and PCa (serum and urine) by studying different cohort studies.

Financial Disclosure

Board Memberno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: